These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9813 related articles for article (PubMed ID: 17689990)
1. Significance of eIF4E expression in skin squamous cell carcinoma. Salehi Z; Mashayekhi F; Shahosseini F Cell Biol Int; 2007 Nov; 31(11):1400-4. PubMed ID: 17689990 [TBL] [Abstract][Full Text] [Related]
2. The expression of proto-oncogene eIF4E in laryngeal squamous cell carcinoma. Liang Z; Lei T; LuYing Z; YuPing G Laryngoscope; 2003 Jul; 113(7):1238-43. PubMed ID: 12838026 [TBL] [Abstract][Full Text] [Related]
3. Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells. Goldson TM; Vielhauer G; Staub E; Miller S; Shim H; Hagedorn CH Mol Carcinog; 2007 Jan; 46(1):71-84. PubMed ID: 17091471 [TBL] [Abstract][Full Text] [Related]
4. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Salehi Z; Mashayekhi F Clin Biochem; 2006 Apr; 39(4):404-9. PubMed ID: 16375881 [TBL] [Abstract][Full Text] [Related]
5. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707 [TBL] [Abstract][Full Text] [Related]
6. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. Sorrells DL; Meschonat C; Black D; Li BD J Surg Res; 1999 Jul; 85(1):37-42. PubMed ID: 10383835 [TBL] [Abstract][Full Text] [Related]
7. Expression of RUNX3 in skin cancers. Lee JH; Pyon JK; Kim DW; Lee SH; Nam HS; Kang SG; Kim CH; Lee YJ; Chun JS; Cho MK Clin Exp Dermatol; 2011 Oct; 36(7):769-74. PubMed ID: 21623876 [TBL] [Abstract][Full Text] [Related]
8. Proteinase-activated receptor-2 expression in basal and squamous cell carcinomas compared with normal skin. Dastgheib L; Monabati A; Mohammadian A; Sari-Aslani F; Marzban S; Namazi MR J Cutan Pathol; 2009 Mar; 36(3):314-7. PubMed ID: 19032384 [TBL] [Abstract][Full Text] [Related]
9. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Seki N; Takasu T; Mandai K; Nakata M; Saeki H; Heike Y; Takata I; Segawa Y; Hanafusa T; Eguchi K Clin Cancer Res; 2002 Oct; 8(10):3046-53. PubMed ID: 12374671 [TBL] [Abstract][Full Text] [Related]
10. [Correlation between prognosis and the expression of eukaryotic translation initiation factor 4E in surgical margin specimen of laryngeal squamous cell carcinoma]. Xia LP; Xu GP; Zeng ZY; Rao HL; Zeng J; Hou JH Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Apr; 38(2):139-42. PubMed ID: 12889116 [TBL] [Abstract][Full Text] [Related]
11. Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Zhu N; Gu L; Findley HW; Zhou M Biochem Biophys Res Commun; 2005 Oct; 335(4):1272-9. PubMed ID: 16112647 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Fogarty GB; Conus NM; Chu J; McArthur G Br J Dermatol; 2007 Jan; 156(1):92-8. PubMed ID: 17199573 [TBL] [Abstract][Full Text] [Related]
13. eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival. Siegele B; Cefalu C; Holm N; Sun G; Tubbs J; Meschonat C; Odaka Y; DeBenedetti A; Ghali GE; Chu Q; Mathis JM; Li BD J Surg Res; 2008 Jul; 148(1):83-9. PubMed ID: 18570935 [TBL] [Abstract][Full Text] [Related]
14. Expression of p53 in the evolution of squamous cell carcinoma: correlation with the histology of the lesion. Barzilai A; Lyakhovitsky A; Trau H; Fogel M; Huszar M J Am Acad Dermatol; 2007 Oct; 57(4):669-76. PubMed ID: 17870432 [TBL] [Abstract][Full Text] [Related]
15. 5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma. Srivastava RK; Khan J; Arumugam A; Muzaffar S; Guroji P; Gorbatyuk MS; Elmets CA; Slominski AT; Mukhtar MS; Athar M J Invest Dermatol; 2021 Apr; 141(4):742-753.e10. PubMed ID: 32971126 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Kapucuoglu N; Basak PY; Bircan S; Sert S; Akkaya VB Pathol Res Pract; 2009; 205(2):97-103. PubMed ID: 18951731 [TBL] [Abstract][Full Text] [Related]
17. The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Zhang X; Egawa K; Xie Y; Ihn H Int J Dermatol; 2009 Jun; 48(6):579-83. PubMed ID: 19538364 [TBL] [Abstract][Full Text] [Related]
18. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Graff JR; Konicek BW; Carter JH; Marcusson EG Cancer Res; 2008 Feb; 68(3):631-4. PubMed ID: 18245460 [TBL] [Abstract][Full Text] [Related]
19. Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism. Brouxhon S; Kyrkanides S; O'Banion MK; Johnson R; Pearce DA; Centola GM; Miller JN; McGrath KH; Erdle B; Scott G; Schneider S; VanBuskirk J; Pentland AP Cancer Res; 2007 Aug; 67(16):7654-64. PubMed ID: 17699770 [TBL] [Abstract][Full Text] [Related]
20. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Graff JR; Konicek BW; Lynch RL; Dumstorf CA; Dowless MS; McNulty AM; Parsons SH; Brail LH; Colligan BM; Koop JW; Hurst BM; Deddens JA; Neubauer BL; Stancato LF; Carter HW; Douglass LE; Carter JH Cancer Res; 2009 May; 69(9):3866-73. PubMed ID: 19383915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]